Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Ascletis Pharma

Ascletis Pharma

A biotechnology company that develops and discovers anti-viral drugs and treatments for cancer and fatty liver disease. Ascletis is a joint venture between entrepreneurs in the U.S. and China.

Ascletis Pharma is a biotechnology company that develops and discovers anti-viral drugs and treatments for cancer and fatty liver disease. Ascletis is a joint venture between entrepreneurs in the U.S. and China.

Ascletis’s Ganovo, an oral inhibitor of Hepatitis C protease and ritonavir a protease inhibitor from AbbVie were used in combination in a clinical trial at the Ninth Hospital of Nanchang, China, led by Dr. Hongyi Chen, for treatment of COVID-19. Three patients were discharged after the treatment as of February 27, 2020. Ganovo received approval from China’s National Medical Products Administration in June, 2018 for treatment of Hepatitis C. The company’s protease inhibitor ASC09 is also in clinical trials in combination with other drugs for treatment of COVID-19.

COVID-19

Since the outbreak of COVID-19, Ascletis Pharma has announced that they are treating three patients treated with Ganovo plus Ritonavir as part of a novel coronavirus pneumonia clinical trial that occured in China and were dischared from the hospital. Ganovo is a oral inhibitor of Hepatitis C virus and is approved by the FDA to treat HIV infections in people. The company looks to work with the patients that were discharged to develop anti-viral drugs to be used in clinical studies on the treatment of HCP.

Timeline

June 7, 2021
Ascletis Pharma Inc. announces that China National Medical Products Administration has approved the Investigational New Drug application for its drug candidate ASC42.
January 3, 2017
Ascletis Pharma raises a $100,000,000 series B round.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Ascletis Pharma Inc.
June 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational...
Ascletis Pharma Inc.
May 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field...
Ascletis Pharma Inc.
May 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration...
Ascletis Pharma Inc.
May 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) today announces the positive Phase IIa clinical results of ASC22 (Envafolimab), which is a first-in-class,...
BioSpace
April 14, 2021
BioSpace
Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the dosing of the first cohort in the U.S. Phase I clinical study of drug interaction and non-alcoholic fatty liver disease
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.